Home/Pipeline/AdOral® Insulin

AdOral® Insulin

Diabetes

PreclinicalPlatform Development

Key Facts

Indication

Diabetes

Phase

Preclinical

Status

Platform Development

Company

Adocia

About Adocia

Adocia is a clinical-stage biotechnology company focused on developing innovative formulations and delivery systems for metabolic diseases, primarily diabetes and obesity. The company's strategy is built on four proprietary technology platforms (BioChaperone®, AdoShell®, AdOral®, AdoXLong) designed to enhance the efficacy and delivery of peptides, proteins, and cell therapies. Key achievements include advancing a Phase 3 ultra-rapid insulin and securing partnerships with major pharmaceutical firms like Eli Lilly and Tonghua Dongbao. Adocia's business model involves licensing out its validated assets post-proof-of-concept to global partners for development and commercialization.

View full company profile

Therapeutic Areas

Diabetes Obesity

Other Diabetes Drugs

Drug	Company	Phase	Status
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active
Glucose-Responsive Insulin Receptor Agonist	Protomer Technologies	Pre-clinical (integrated into Lilly pipeline)	Active
Analog Insulin Aspart	Paras Biopharmaceuticals Finland	Pre-clinical	Active